BIAFW — bioAffinity Technologies, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1712762 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,351,527 | 422,891 | -3,616,976 | -3,630,610 | 7,945,252 | 3,098,366 | 4,283,866 |
| Dec 2025 | 1,538,813 | 638,687 | -3,190,963 | -3,137,466 | 10,960,772 | 6,449,782 | 3,683,116 |
| Sep 2025 | 1,446,066 | 503,855 | -2,292,846 | -5,051,084 | 11,546,369 | 7,669,195 | 2,644,171 |
| Jun 2025 | 1,269,483 | 252,881 | -2,515,560 | -4,060,787 | 4,751,075 | 802,835 | 6,887,183 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,914,307
Investing CF
$-15,445
Financing CF
$13,583,412
CapEx
$-69,877
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,184,674
Inventory
$77,887
Receivables
$685,235
ST Investments
—
EBIT TTM
$-15,800,991
Pretax Income TTM
$-15,844,600
Interest Exp TTM
$43,609
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,900,985
EBITDA
$-11,968,556
Free Cash Flow
$-6,909,285
Enterprise Value
—
Total Cash
$2,429,719
Total Debt
$1,435,005
Shares Out
—
Trailing EPS
—
Book Value
$0.56
ROE
-1860.2%
ROA
-125.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,107,959 | -10,626,508 | -14,909,754 | 10,960,772 | 3,683,116 | — | -9,328,842 |
| Dec 2024 | 9,362,022 | -8,953,445 | -9,039,831 | 6,513,667 | 3,911,631 | — | -7,264,795 |
| Dec 2023 | 2,532,499 | -7,973,228 | -7,937,011 | 8,221,552 | 3,366,297 | — | -6,037,806 |
| Dec 2022 | 4,803 | -4,011,058 | -8,154,113 | 12,182,125 | 1,138,682 | — | -4,070,845 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.14B | $559.51 | — |
| IQV | IQVIA HOLDINGS INC. | $42.84B | $260.24 | — |
| INCY | INCYTE CORP | $25.94B | $127.98 | — |
| MEDP | Medpace Holdings, Inc. | $17.31B | $620.03 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $14.25B | $298.58 | — |
News headlines (Yahoo Finance, 1h cache)
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
2026-06-22 12:00 · Yahoo
bioAffinity Technologies Announces Closing of $3.2 Million Offering
2026-06-18 17:16 · Yahoo
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
2026-06-17 14:40 · Yahoo
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
2026-08-20 12:00 · Yahoo
bioAffinity Technologies Signs Nationwide Federal Healthcare Distribution Agreement for CyPath Lung
2026-08-18 14:43 · Yahoo
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
2026-08-18 12:00 · Yahoo
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
2026-08-14 15:45 · Yahoo
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
2026-08-14 15:07 · Yahoo
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
2026-08-13 14:00 · Yahoo
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
2026-08-13 13:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.